Article Title

Expert Consensus on Long-acting Injectable Antipsychotic in the Treatment of Schizophrenia in Community


Tianmei Si


Schizophrenia is a chronic, recurrent and disabling psychotic disorder. Improving patients' adherence and preventing relapse are key points in the treatment of schizophrenia, as well as the core factors to determine patients' prognosis and social function recovery. Long-acting injectable (LAI) is an important treatment strategy and recurrent prevention of schizophrenia, which is recommended by guidelines/consensus as one of the preferred treatment methods for the all schizophrenia. At the same time, community as an important site for the rehabilitation of schizophrenia, some community management models have been carried out recently. At present, a series of policies and documents stressed the application of LAI in the management of schizophrenia in community. However, some community mental health workers are lack of experience and application skills of LAI, which affects the application of LAI in the community and become one of the bottlenecks for the rehabilitation of patients. Therefore, under the organization of the Chinese Schizophrenia Coordination Group and Chinese Society of General Practice, 13 experts formed the expert group members of this consensus, which based on the evidence-based medical suggestion, domestic and international guidelines and consensus, experts experience and the characteristics of Chinese community. In order to solve medical problems in the community LAI application and improve the compliance and prognosis of schizophrenia of patients.